BNP Paribas Asset Management
MDGL icon

BNP Paribas Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

BNP Paribas Asset Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.2M Sell
31,998
-881
-3% -$451K 0.02% 614
2026
Q1 		$17.2M Buy
32,879
+17,532
+114% +$8.38M 0.02% 571
2025
Q4 		$8.94M Buy
15,347
+15,210
+11,102% +$7.77M 0.01% 705
2025
Q3 		$63K Buy
137
+5
+4% +$1.86K ﹤0.01% 981
2025
Q2 		$40K Buy
+132
New +$39.3K ﹤0.01% 1222

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BNP Paribas Asset Management's MDGL Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Madrigal Pharmaceuticals (MDGL) stake by 2.7% in Q2 2026, selling an estimated $451K and leaving 31,998 shares worth $17.2M. The position accounts for 0.02% of the portfolio, ranked #614.

BNP Paribas Asset Management first reported a position in MDGL in Q2 2025 and has held it in 5 quarters since. The position peaked at $17.2M in Q1 2026. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • BNP Paribas Asset Management held 31,998 shares of Madrigal Pharmaceuticals worth $17.2M as of Q2 2026.
  • BNP Paribas Asset Management sold 881 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $451K.
  • Madrigal Pharmaceuticals made up 0.02% of BNP Paribas Asset Management's portfolio in Q2 2026, its #614 holding.
  • BNP Paribas Asset Management first reported a position in Madrigal Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • BNP Paribas Asset Management's Madrigal Pharmaceuticals position peaked at $17.2M in Q1 2026.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.